20.06.2024 news

Interview in "BioTechnologie Kursbuch No. 37"

We are happy to be featured in this year's “BioTechnologie Kursbuch”. The interview from Georg Kääb with our CEO Prof. Dr. Hartmut Juhl covers an overview on the latest insights on the oncology R&D industry, what part AI has within this and what we believe truly matters.

11.06.2024 news

The untapped power of multivariate analysis for target identification in cancer drug discovery - a LaBiotech Article

Is multivariate analysis the solution to identify targets in cancer drug discovery? We are pleased to be featured in the article from LaBiotech, that will provide an overview on the novel target identification process in pre-clinical oncology research, focusing on the computational/mathematical perspective into target ID.

15.04.2024 news

Indivumed Omics Hub and Clinical Network Collaborations Powering Precision Medicine Research Publications

Indivumed GmbH announced the fourth research publication enabled by the Indivumed Omics Hub. An interface for members of the Indivumed Global Clinical Network, the Omics Hub provides clinicians with direct access to curated multi-omics data derived from their patients. With access to both individual and cohort data, the Omics Hub enables quick and efficient precision oncology research.

07.12.2023 news

BIO Deutschland Yearbook 2023/2024

We are pleased to again be featured in the BIO Deutschland Yearbook for 2023/2024 and proud to be a part of the rapidly growing European biotech industry, looking forward to continuing our success in 2024. Read our feature interview and profile here.

11.12.2023 news

Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg

Onco AI-Med is an international collaborative alliance founded by Indivumed to advance personalized medicine in cancer by bringing together the combined knowledge and experience of oncologists from leading cancer clinics and research institutions around the world. Indivumed Therapeutics welcomed members of the Oncology Alliance For Individualized Medicine to its global headquarters in Hamburg, Germany for the Onco AI-Med annual board meeting.

28.11.2023 news

Standardizing tissue quality: Your key to accurate early discovery insights

In precision oncology, tissue quality plays a pivotal role in maintaining data integrity. We explore the impact of standardizing tissue collection and processing on data quality, and how this helps enhance patient outcomes as well as our understanding of cancer.

21.09.2023 news

Precision therapeutics: optimizing early discovery

Precision medicine tailors therapeutics to individual patients’ diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.

28.07.2023 news

Where the medicine of the future is already being lived in the present

More than 20 years ago, Indivumed set out to create a solid database for the individualized cancer therapy of the future. Today, founder and CEO Prof. Dr. Hartmut Juhl considers himself to have made considerable progress along this path, not least thanks to his company's unique database. In an interview with Wirtschaftsforum, the passionate entrepreneur talked about the future prospects.

24.07.2023 news

Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach

Read our at MDPI newly published paper on "Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach".

06.06.2023 news

Optimizing early discovery within precision therapeutics

Precision medicine involves tailoring a therapeutic to a patients’ disease. Here, we delve into the critical role played by the quality of the samples, the data, and the analysis in the development of these targeted therapies. Read the full article.

23.12.2022 news

Ending the year - Today. Tomorrow. Together.

A review on 2022 and Indivumed's 20 year long history, and outlook, and thank you

Get in touch with Indivumed at BioTechX in Basel in October.

We look forward to connecting with you at BioTechX in Basel, October 9-10, 2024.

Connect with us at Bio-Europe in Stockholm this year.

Meet the Indivumed Team on site and get in touch with us in Stockholm from November 4-6, 2024.

08.04.2024 poster

Poster Bischof et al. 2024 Deciphering chromosomal instability in consensus molecular Subtypes (CMS) in CRC: Insights from an integrative multi-omics approach

30.04.2024 publication

Scimeca, M. et. al Molecular profiling of a bladder cancer with very high tumour mutational burden, Cell Death Discovery 10:202 (2024)

21.03.2024 publication

Scimeca, M. et al. Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma, Discover Oncology 15:80 (2024)

16.01.2024 publication

Mengting Zhu et. al Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype Discover Oncology 15:10 (2024)

21.10.2023 poster

Poster Bischof et al. 2023 Combining cancer patient spatial transcriptomics and bulk rna-seq data to drive insights into NSCLC

09.10.2023 publication

Yuyi, H. et al. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient Cell Death Discovery 9, 370 (2023)

02.10.2023 publication

Yang, X. et al A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency Cell Death Discovery 9, 365 (2023)

03.09.2023 publication

Michalska-Falkowska et al. MDPI 2023 Applied Molecular-Based Quality Control of Biobanked Samples for Multi-Omics Approach

26.08.2021 poster

Poster Marshall et al. 2021 Multi-omics characterization markers of left and right-sided colorectal cancer